Pharma Archives - Page 21 of 80 - Life Sciences Times

Vertex Teams Up with Jayson Tatum to Highlight JOURNAVX, a Non-Opioid Pain Medicine

September 23, 2025

Meet the Man Behind FDA-Approved Bladder Cancer Breakthrough: Dr. Purnanand Sarma and the Journey of INLEXZO™

September 22, 2025

Blue Cross Blue Shield of Massachusetts Appoints Sophie Clarke as Chief Strategy Officer

September 19, 2025

THIS WEEK'S STORIES

Dr. Vince Clinical Research Begins Dosing in Phase 1b Trial of Enveda’s Investigational Drug ENV-294 for Atopic Dermatitis

September 16, 2025

BostonGene Named Platinum Winner for AI Research Innovation at 2025 Pinnacle Awards

September 17, 2025

FDA Approves Johnson & Johnson’s INLEXZO™ for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

September 16, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Pharma

Actio Biosciences Doses First Participant in Phase 1 Trial of ABS-1230 for KCNT1-Related Epilepsy

FDA Issues Complete Response Letter for Scholar Rock’s Apitegromab, Citing Catalent Facility Observations

Vertex Teams Up with Jayson Tatum to Highlight JOURNAVX, a Non-Opioid Pain Medicine

KalVista Wins EU, Swiss Approvals for EKTERLY, First Oral On-Demand Therapy for Hereditary Angioedema

Nuvation Bio Gains Japan Approval for IBTROZI in Advanced ROS1-Positive Lung Cancer

Most Read

Actio Biosciences Doses First Participant in Phase 1 Trial of ABS-1230 for KCNT1-Related Epilepsy

Study Finds Sensus Healthcare’s SRT with Punch Excision Effective for Treating Keloids

Ncardia Unveils First iPSC-Derived Non-Human Primate Cardiomyocytes for Cardiac Safety Research

Altera Names Sandeep Nayyar Chief Financial Officer

EDITOR PICKS

Vertex Teams Up with Jayson Tatum to Highlight JOURNAVX, a Non-Opioid Pain Medicine

Meet the Man Behind FDA-Approved Bladder Cancer Breakthrough: Dr. Purnanand Sarma and the Journey of INLEXZO™

Blue Cross Blue Shield of Massachusetts Appoints Sophie Clarke as Chief Strategy Officer

THIS WEEK'S STORIES

Dr. Vince Clinical Research Begins Dosing in Phase 1b Trial of Enveda’s Investigational Drug ENV-294 for Atopic Dermatitis

BostonGene Named Platinum Winner for AI Research Innovation at 2025 Pinnacle Awards

FDA Approves Johnson & Johnson’s INLEXZO™ for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

POPULAR CATEGORY

ABOUT US

FOLLOW US